Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis + enterococcus faecalis
- Development stage
- Preclinical
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis + Enterococcus faecalis is a combination probiotic product used to support gut health. The product contains live bacterial strains of Bacillus subtilis and Enterococcus faecalis, which are considered beneficial bacteria naturally found in the human gut. This combination is used to treat and prevent gastrointestinal issues such as diarrhea, constipation, and irritable bowel syndrome (IBS) by modulating the intestinal microbiota. [1-1, 1-11, 8] It is also being studied for preventing ventilator-associated pneumonia. [7, 12] The product is available in different formulations, including granules and capsules. It is marketed under various brand names, such as Mamiai (妈咪爱) and Meichangan (美常安) by Beijing Hanmi Pharmaceutical. [2, 3, 8]
- Brand names
- 妈咪爱Mamiai美常安Medilac
- Other names
- 枯草杆菌二联活菌
Beyond the preview
Go deeper on bacillus subtilis + enterococcus faecalis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis + enterococcus faecalis.